Τίτλος:
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): A randomised, multicentre, double-blind, placebo-controlled phase 3 trial
Συγγραφείς:
Monk, B.J.
Poveda, A.
Vergote, I.
Raspagliesi, F.
Fujiwara, K.
Bae, D.-S.
Oaknin, A.
Ray-Coquard, I.
Provencher, D.M.
Karlan, B.Y.
Lhommé, C.
Richardson, G.
Rincón, D.G.
Coleman, R.L.
Herzog, T.J.
Marth, C.
Brize, A.
Fabbro, M.
Redondo, A.
Bamias, A.
Tassoudji, M.
Navale, L.
Warner, D.J.
Oza, A.M.
Λέξεις-κλειδιά:
bevacizumab; cediranib; paclitaxel; trebananib, blood vessel; cancer adjuvant therapy; cancer chemotherapy; cancer recurrence; cancer staging; drug industry; drug receptor binding; drug targeting; human; multicenter study (topic); Note; oncologist; ovary cancer; phase 3 clinical trial (topic); progression free survival; randomized controlled trial (topic)
